A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition
The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter…
Certara2025年4月30日
Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications
Vice President, MBMA Capability Lead, Certara Drug Development Solutions Matt advances the integration of published…
Certara2025年4月10日
Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]
Vice President, Quantitative Science Services, Certara Matt advances the integration of published clinical outcomes data…
Certara2025年4月3日
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…
Certara2025年2月25日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Certara2025年1月9日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
Certara2025年1月8日
Using MBMA to run virtual “head-to-head trials”
Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…
Certara2023年4月21日
